Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified DEP Regimen in Lymphoma-Induced HLH
NCT04077905Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin in hemophagocytic lymphohistiocytosis (HLH), sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT04077905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077905.